Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature

Abstract

Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.

Metastatic salivary duct carcinoma presenting as cannonball lung lesions on radiology: Case Report

“…Chemotherapy, commonly anti-androgen rather than cytotoxic, is considered for patients with distant metastases or palliatively (Kantamani et al, 2021;Nakaguro, et al, 2018). Several studies reported use of androgen deprivation therapy with androgen receptor inhibitors as monotherapy or in combination with gonadotropin hormone-releasing hormone, luteinizing hormone-releasing agonists or HER-2 targeted therapy and a taxane (Eveson, 2006; Matsumiya-Matsumoto, et al, 2022).…”